Investigation of pathophysiological roles of transporter for antioxidant with an aim to develop pharmacotherapeutics of inflammatory organ diseases
Project/Area Number |
24390040
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | Kanazawa University |
Principal Investigator |
Kato Yukio 金沢大学, 薬学系, 教授 (30251440)
|
Co-Investigator(Renkei-kenkyūsha) |
SAKAI Yoshio 金沢大学, 医学系, 准教授 (80401925)
WAKAYAMA Tomohiko 金沢大学, 医学系, 准教授 (70305100)
NAKAMICHI Noritaka 金沢大学, 薬学系, 准教授 (10401895)
SUGIURA Tomoko 金沢大学, 薬学系, 助教 (70542190)
|
Research Collaborator |
MASUO Yusuke 金沢大学, 薬学系, 助教 (90708140)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥14,040,000 (Direct Cost: ¥10,800,000、Indirect Cost: ¥3,240,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
|
Keywords | 薬物動態 / 膜輸送体 / 慢性臓器疾患 / 薬物治療 / 抗酸化物質 / 薬物動態・代謝学 |
Outline of Final Research Achievements |
The purpose of the present project is to establish the strategy to prevent and/or treat with chronic inflammatory diseases in various organs using a certain transporter which is highly expressed in the diseased lesions. Transporters are generally involved in membrane transport (influx and/or efflux) of their substrates. Therefore, transporters highly expressed in diseased lesions could be a possible target which can be used to prevent and/or treat with the corresponding diseases. This project has revealed that a certain transporter is highly expressed in diseased lesions of liver fibrosis and inflammatory bowel disease models, and that the transporter is involved in uptake of a food-derived naturally occurring antioxidant in the diseased organs, leading to suppression of deterioration of those diseases. Thus, the present findings have proposed a new strategy for pharmacotherapy of those diseases using potent antioxidant and/or thepeutic agents targeted to the transporter.
|
Report
(4 results)
Research Products
(48 results)
-
-
-
-
-
-
-
[Journal Article] Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans2014
Author(s)
Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y and Kato Y
-
Journal Title
Pharm Res
Volume: 31(1)
Pages: 204-215
DOI
Related Report
Peer Reviewed
-
[Journal Article] Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin2013
Author(s)
Nakamichi N, Shima H, Asano S, Ishimoto T, Sugiura T, Matsubara K, Kusuhara H, Sugiyama Y, Sai Y, Miyamoto KI, Tsuji A, Kato Y
-
Journal Title
J Pharm Sci
Volume: 102(9)
Pages: 3407-3417
DOI
Related Report
Peer Reviewed
-
[Journal Article] Displays of mouse pup retrieval as paternal parental behaviour following communicative interaction with maternal mates2013
Author(s)
Liu H-X, Lopatina O, Higashida C, Fujimoto H, Akther S, Inzhutova A, Liang M, Zhong J, Tsuji T, Yoshihara T, Sumi K, Ishiyama M, Ma W-J, Ozaki M, Yagitani S, Yokoyama S, Mukaida N, Sakurai T, Hori O, Yoshioka K, Hirao A, Kato Y et al.
-
Journal Title
Nat Commun
Volume: 4
Pages: 1346
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-